About this webinar:
Despite the successful implementation of several public health interventions, cigarette smoking remains a leading cause of morbidity and mortality. Although several smoking cessation therapies exist, most individuals will relapse when they attempt to quit. Over the last several years, individuals who smoke have increasingly turned to e-cigarettes as a smoking cessation aid. However, the efficacy of e-cigarettes for smoking cessation remains unclear. The Evaluating the Efficacy of E-Cigarette Use for Smoking Cessation (E3) Trial randomised participants to nicotine e-cigarettes, non-nicotine e-cigarettes, or no e-cigarettes for 12 weeks, with all groups receiving individual counselling. This seminar will present the 52-week results of the E3 Trial.
About this speaker:
Kristian Filion is an Associate Professor and William Dawson Scholar in the Departments of Medicine and of Epidemiology, Biostatistics, and Occupational Health, at McGill University and a Senior Investigator at the Centre for Clinical Epidemiology of the Lady Davis Institute of the Jewish General Hospital in Montreal, Canada. His research interests include pharmacoepidemiology and drug safety, knowledge synthesis, and cardiovascular epidemiology. He uses large, population-based databases to study the utilization, effectiveness, and safety of commonly prescribed medications, with a particular interest in cardiometabolic conditions (hypertension, heart disease, and diabetes), including studies of drugs used to treat them and cardiometabolic outcomes. He is a Steering Committee Member of the Canadian Network for Observational Drug Effect Studies (CNODES), a pan-Canadian network that addresses drug safety and effectiveness for the government.